Navigation Links
Researchers discover how underground rodent wards off cancer
Date:11/5/2012

Biologists at the University of Rochester have determined how blind mole rats fight off cancerand the mechanism differs from what they discovered three years ago in another long-lived and cancer-resistant mole rat species, the naked mole rat.

The team of researchers, led by Professor Vera Gorbunova and Assistant Professor Andrei Seluanov, found that abnormally growing cells in blind mole rats secrete the interferon beta protein, which causes those cells to rapidly die. Seluanov and Gorbunova hope the discovery will eventually help lead to new cancer therapies in humans. Their findings are being published this week in the Proceedings of the National Academy of Sciences.

Blind mole rats and naked mole ratsboth subterranean rodents with long life spansare the only mammals never known to develop cancer. Three years ago, Seluanov and Gorbunova determined the anti-cancer mechanism in the naked mole rat. Their research found that a specific genep16makes the cancerous cells in naked mole rats hypersensitive to overcrowding, and stops them from proliferating when too many crowd together.

"We expected blind mole rats to have a similar mechanism for stopping the spread of cancerous cells," said Seluanov. "Instead, we discovered they've evolved their own mechanism."

Gorbunova and Seluanov made their discovery by isolating cells from blind mole rats and forcing them to proliferate in culture beyond what occurs in the animal. After dividing approximately 15-20 times, all of the cells in the culture dish died rapidly. The researchers determined that the rapid death occurred because the cells recognized their pre-cancerous state and began secreting a suicidal protein, called interferon beta. The precancerous cells died by a mechanism which kills both abnormal cells and their neighbors, resulting in a "clean sweep."

"Not only were the cancerous cells killed off, but so were the adjacent cells, which may also be prone to tumor
'/>"/>

Contact: Peter Iglinski
peter.iglinski@rochester.edu
585-273-4726
University of Rochester
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Forum to bring together leading-edge ophthalmic researchers and investors
2. George Mason University researchers target breast cancer in 3 trials
3. IU researchers report first effective treatment of tumors arising from common genetic disease NF1
4. OHSU researchers discover potential way to repair brain damage in multiple sclerosis
5. Penn researchers find error reporting improves perceptions of safety and may reduce incidents
6. Common Antidepressants Too Risky During Pregnancy, Researchers Say
7. Mechanism found for destruction of key allergy-inducing complexes, Stanford researchers say
8. Feinstein Institute researchers discover that bean used in Chinese food could protect against sepsis
9. Mayo Clinic researchers develop new tools to better treat ADHD patients in early stages
10. Moffitt Researchers find genetic predictors of fatigue for some prostate cancer patients
11. Penn Medicine researchers map strategy for choosing wisely on low-value health care services
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers discover how underground rodent wards off cancer
(Date:12/22/2014)... Fad diets have been around forever ... most fad diets have hung around so long is that ... is that, as the body becomes accustomed to new eating ... to reset the metabolism to return the body to fast ... all-inclusive diet plans that are medically supervised throughout. ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic consulting company, ... ad hoc report writing service to meet the high ... for an annual subscription and get a fixed number ... discounted hourly rate. , Customers can choose from ... rate. Subscription hours are contracted in 25 hour increments. ...
(Date:12/22/2014)... On December 22, 2014, My Positive Perspective ... for an episode to celebrate Christmas. At the beginning ... so important to you that we all appreciate and ... should respect who Jesus was. I think sometimes we ... That means that on Jesus’ birthday we remember that ...
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... SUNDAY, Dec. 21, 2014 (HealthDay News) -- A new ... cow disease" in deer might also protect livestock and ... The vaccine appears to help prevent deer from becoming ... wasting disease, according to the report in the Dec. ... Chronic wasting disease is caused by mysterious infectious particles ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), a leading ... to present at the Jefferies 3rd Annual Healthcare Conference in New ... 2009. , , The presentations will be available to ... accessed by visiting http://investors.gentiva.com/events.cfm . Visitors ...
... ... New hope for a much needed new approach for tackling Alzheimer,s disease ... in Philadelphia. At the inaugural Targeting Alzheimer,s with Novel Therapeutics conference, ... Edward Tobinick MD, Director of the Institute for Neurological Research, a private ...
... Men Fly off the Shelves for Father,s Day , , ... for chronic lower back pain may lie in a $59.99 biomechanically-engineered ... be the turning point for the sixty million adults who reported ... shoe many claim to be a medical breakthrough is now available ...
... Inc. a technology and services company focused on global eClinical solutions ... 45th DIA Annual Meeting to be held later this month in ... well as a number of exciting new features and functionality in ... , Reaffirming our ...
... More Efficient Operation for Gateway Healthcare , , ... announced today that it is addressing the ... with the unique, next generation voice product, Cox ... moved its telecommunications services from a competitive provider to ...
... Over Half a Million Varicose Vein Patients Treated with VNUS Closure ... VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS ), a worldwide ... venous reflux disease , the underlying cause of ... week, it estimates the number of patients treated with the VNUS ...
Cached Medicine News:Health News:Gentiva(R) Health Services to Present at Jefferies 3rd Annual Healthcare Conference 2Health News:Gentiva(R) Health Services to Present at Jefferies 3rd Annual Healthcare Conference 3Health News:New Immune Approach for Treatment of Alzheimer's Disease 2Health News:New Immune Approach for Treatment of Alzheimer's Disease 3Health News:New Immune Approach for Treatment of Alzheimer's Disease 4Health News:One of Women's Best Kept Secrets is Now Available in the Men's Department 2Health News:DATATRAK Announces New Products and Features at DIA San Diego 2Health News:DATATRAK Announces New Products and Features at DIA San Diego 3Health News:DATATRAK Announces New Products and Features at DIA San Diego 4Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 2Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 3Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 4Health News:A Milestone of Opportunity for VNUS Medical Technologies 2Health News:A Milestone of Opportunity for VNUS Medical Technologies 3
(Date:12/22/2014)... DIEGO , Dec. 22, 2014  Pfenex Inc. ... Pfenex,s recombinant anthrax vaccine, has been filed and is ... funding provided by the Department of Health and Human ... Authority (BARDA). "We are extremely pleased to ... vaccine, Px563L.  This represents a significant milestone in our ...
(Date:12/22/2014)... -- TWi Biotechnology, Inc., today announced that it ... Biotechnology,s lead drug candidate, from The State Intellectual ... for patent application numbered 201180018154.8.  This patent includes ... for treatment of type II diabetes.  The patent ... for type II diabetes, and provides a protection ...
(Date:12/19/2014)... , December 19, 2014 TODAY, ... in the World announced the appointment of Peter ... Vonsée, as Chief Channels and Partner Officer. ... 2004 through to its acquisition by Oracle in 2011. ... at Geneva and subsequently Convergys, ...
Breaking Medicine Technology:Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4
... Aggregate Benefit over Placebo Larger at One Year ... June 11, 2007,/PRNewswire-FirstCall/ -- Medivation, Inc. today announced ... double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer's,disease ... 12 months. Importantly, on every endpoint studied, the ...
... 2007 /PRNewswire/ -- GlaxoSmithKline,plc announced results from ... investigational non-peptide oral platelet growth,factor, PROMACTA(R) (eltrombopag ... at 50-75mg once daily resulted in a,statistically ... bleeding in adult patients with chronic idiopathic,thrombocytopenic ...
Cached Medicine Technology:Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 2Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 3Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 4Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 5Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 6
Bravo Vacuum Pump. Complete with tubing....
Stand with buffer tubes for calibration of Bravo pH capsule....
... lower esophhageal sphincter (LES) can ... a separate manometry system. pH ... identification accessory kit and Digitrapper ... locate the LES. The kit ...
pH Calibration Stand with two Sealable Buffer Tubes 1 set....
Medicine Products: